title: Metformin and cancer: Technical and clinical implications for FDG-PET imaging.
abstract: Metformin is the most widely used hypoglycemic agent. Besides its conventional indications, increasing evidence demonstrate a potential efficacy of this biguanide as an anticancer drug. Possible mechanisms of actions seem to be independent from its hypoglycemic effect and seem to involve the interference with key pathways in cellular proliferation and glycolysis. To date, many clinical trials implying the use of metformin in cancer treatment are on-going. The increasing use of (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in cancer evaluation raises a number of questions about the possible interference of the biguanide on FDG distribution. In particular, the interferences exerted by metformin on AMP-activated protein kinase pathway (the cellular energy sensor), on insulin levels and on Hexokinase could potentially have repercussion on glucose handling and thus on FDG distribution. A better comprehension of the impact of metformin on FDG uptake is needed in order to optimize the use of PET in this setting. This evaluation would be useful to ameliorate scans interpretation in diabetic patients under chronic metformin treatment and to critically interpret images in the context of clinical trials. Furthermore, collecting prospective data in this setting would help to verify whether FDG-PET could be a valid tool to appreciate the anticancer effect of this new therapeutic approach.
authors.affiliation: Selene Capitanio, Gianmario Sambuceti, Silvia Morbelli, Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Department of Health Sciences, University of Genoa, 16132 Genoa, Italy.
authors.forename: Selene
authors.initials: S
authors.lastname: Capitanio
authors.affiliation: Selene Capitanio, Gianmario Sambuceti, Silvia Morbelli, Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Department of Health Sciences, University of Genoa, 16132 Genoa, Italy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Marini
authors.affiliation: Selene Capitanio, Gianmario Sambuceti, Silvia Morbelli, Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Department of Health Sciences, University of Genoa, 16132 Genoa, Italy.
authors.forename: Gianmario
authors.initials: G
authors.lastname: Sambuceti
authors.affiliation: Selene Capitanio, Gianmario Sambuceti, Silvia Morbelli, Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Department of Health Sciences, University of Genoa, 16132 Genoa, Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Morbelli
keywords: 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography; Cancer; Diabetes; Glucose metabolism; Metformin
references.citation: J Clin Invest. 2013 Sep;123(9):3693-700
references.pmid: 23999444
references.citation: Med Oncol. 2012 Jun;29(2):1314-27
references.pmid: 21301998
references.citation: N Engl J Med. 2008 Jan 3;358(1):47-54
references.pmid: 18172174
references.citation: J Clin Invest. 2006 Jul;116(7):1776-83
references.pmid: 16823475
references.citation: Cancer Discov. 2012 Sep;2(9):778-90
references.pmid: 22926251
references.citation: Cancer Epidemiol. 2013 Jun;37(3):207-18
references.pmid: 23352629
references.citation: Eur J Nucl Med Mol Imaging. 2010 May;37(5):1011-7
references.pmid: 20107796
references.citation: Clin Nucl Med. 2011 Jun;36(6):452-6
references.pmid: 21552023
references.citation: J Clin Psychiatry. 2013 May;74(5):e424-30
references.pmid: 23759461
references.citation: Oncogene. 2011 Mar 10;30(10):1174-82
references.pmid: 21102522
references.citation: Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61
references.pmid: 20947488
references.citation: Sci Rep. 2013;3:2070
references.pmid: 23797762
references.citation: Neurology. 1982 Dec;32(12 ):1323-9
references.pmid: 6983044
references.citation: Nat Rev Cancer. 2002 Sep;2(9):683-93
references.pmid: 12209157
references.citation: Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):95-9
references.pmid: 17786437
references.citation: Nat Rev Cancer. 2008 Dec;8(12):915-28
references.pmid: 19029956
references.citation: J Nucl Med. 2013 Feb;54(2):252-8
references.pmid: 23376854
references.citation: J Biol Chem. 2000 Jan 7;275(1):223-8
references.pmid: 10617608
references.citation: J Nucl Med. 2013 Feb;54(2):259-66
references.pmid: 23287574
references.citation: Endocr Pract. 2014 Oct;20(10 ):1079-83
references.pmid: 25100379
references.citation: Diabetologia. 1995 Jun;38(6):661-6
references.pmid: 7672486
references.citation: AJR Am J Roentgenol. 2010 Dec;195(6):1404-10
references.pmid: 21098202
references.citation: Nucl Med Biol. 1996 Aug;23 (6):717-35
references.pmid: 8940714
references.citation: Cancer Res. 2007 Jul 15;67(14):6745-52
references.pmid: 17638885
references.citation: Drugs. 1999;58 Suppl 1:55-60; discussion 75-82
references.pmid: 10576527
references.citation: Cell Cycle. 2011 Aug 15;10(16):2770-8
references.pmid: 21811094
references.citation: PLoS One. 2012;7(3):e33411
references.pmid: 22448244
references.citation: Cell Cycle. 2013 Nov 15;12(22):3490-9
references.pmid: 24240433
references.citation: Science. 2005 Dec 9;310(5754):1642-6
references.pmid: 16308421